Portola Pharmaceuticals
E852346
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf | biopharmaceutical company ⓘ |
| acquiredBy | Alexion Pharmaceuticals NERFINISHED ⓘ |
| acquisitionYear | 2020 ⓘ |
| activeIngredientOf |
andexanet alfa
NERFINISHED
ⓘ
betrixaban ⓘ |
| brandNameOf |
Andexxa
NERFINISHED
ⓘ
Bevyxxa NERFINISHED ⓘ Ondexxya NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| developed |
andexanet alfa
NERFINISHED
ⓘ
betrixaban ⓘ |
| developedFor |
prevention of venous thromboembolism
ⓘ
reversal of factor Xa inhibitor anticoagulation ⓘ |
| focusesOn |
anticoagulant reversal agents
ⓘ
factor Xa inhibitors ⓘ hospital-based therapies ⓘ |
| hasAbbreviation | Portola NERFINISHED ⓘ |
| hasDrugClass |
anticoagulant reversal agent
ⓘ
direct oral anticoagulant ⓘ |
| hasTherapyType |
recombinant proteins
ⓘ
small molecule drugs ⓘ |
| headquartersLocation | South San Francisco, California NERFINISHED ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| listedOn | NASDAQ ⓘ |
| market | hospital acute care ⓘ |
| pipelineFocus |
hematologic disorders
ⓘ
thrombosis prevention ⓘ |
| product |
Andexxa
NERFINISHED
ⓘ
Bevyxxa NERFINISHED ⓘ Ondexxya NERFINISHED ⓘ |
| regionServed | global ⓘ |
| regulatoryApproval |
Andexxa FDA approval
ⓘ
Bevyxxa FDA approval ⓘ |
| regulatoryRegion |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| researchArea |
coagulation pathways
ⓘ
factor Xa biology ⓘ thrombotic disorders ⓘ |
| specializesIn |
hematologic conditions
ⓘ
thrombosis therapies ⓘ |
| targetPatientGroup |
patients at risk of venous thromboembolism
ⓘ
patients on factor Xa inhibitors ⓘ |
| therapeuticArea |
cardiovascular disease
ⓘ
hematology ⓘ thromboembolism ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.